Spinraza access in Egypt

A patient-first guide to accessing Spinraza (nusinersen) for spinal muscular atrophy in the Arab Republic of Egypt, through the Egyptian Drug Authority Personal Importation framework and intrathecal administration at qualified Egyptian centers.

Quick orientation

Spinraza is the brand name for nusinersen, the first medicine approved anywhere in the world for the treatment of spinal muscular atrophy (SMA), the rare inherited neuromuscular disease caused by loss-of-function mutations in the SMN1 gene. FDA-approved December 23, 2016, Spinraza covers all SMA types (Type 1, 2, 3, and 4) across all ages. Egypt's elevated consanguinity rate produces a structurally larger SMA case burden than in Western markets, and the country's mature specialty hospital network (Cairo University Hospitals, Ain Shams, Children's Cancer Hospital Egypt 57357 for pediatric coordination, Dar Al Fouad, As-Salam) supports the intrathecal administration the protocol requires. For Egyptian families pursuing Spinraza, the pathway is documented under the Egyptian Drug Authority (EDA) Personal Importation framework, with cold-chain delivery to a Cairo or Alexandria treatment center and intrathecal injection by lumbar puncture on a defined dosing schedule. Reserve Meds coordinates the US-side sourcing and the international cold-chain logistics. Reserved for you.

Why patients in Egypt need Spinraza via NPP

Spinal muscular atrophy is an autosomal recessive disease, and Egypt's high consanguinity rate produces a structurally larger case load than in Western markets. For families with a child diagnosed with SMA Type 1, time-to-first-dose pressure is acute: motor neuron loss is progressive, and every week of delay during early infancy reduces achievable clinical benefit. For SMA Type 2 and Type 3 patients (later-onset, including adolescents and adults), the cadence is steadier but the every-four-months maintenance schedule requires sustained operational continuity over years.

The structural access gap for Spinraza in Egypt sits at the registration-versus-availability seam. Even where Spinraza is registered, public payer access is often gated by SMA type, age at treatment initiation, and severity criteria. Families who fall outside those gates frequently turn to private cross-border supply. In Egypt specifically, where UHIA does not currently cover specialty imports for most patients and where Spinraza is not always stocked at the hospital pharmacy the treating neurologist is working with, the practical path is a named-patient import filed by the treating physician's institution. The intrathecal administration requirement adds a second gate: the treating center must have the procedural capability (lumbar puncture by a trained neurologist, sometimes with interventional radiology guidance for patients with scoliosis or spinal fusion) and willingness to dose imported product.

For Egyptian families coordinating across the diaspora (with relatives in the Gulf, the UK, or North America handling the USD wire), Reserve Meds runs both the patient-side coordination in Arabic and the family-side coordination in English in parallel, with a single named coordinator running the case end to end.

The EDA Personal Importation pathway for Spinraza

The Egyptian Drug Authority was created by Law No. 151 of 2019, issued 25 August 2019 in the Official Gazette No. 34 bis (A), with executive regulations issued by Prime Minister Decision No. 777 of 2020. EDA permits the importation of unregistered or unavailable medicines for a specific named patient under defined conditions, most importantly where no equivalent registered product is available locally, or where the available quantity cannot meet the patient's clinical need. The application is filed through the dispensing institution's import pharmacy.

For Spinraza, the application package centers on a clinical justification letter from the treating neurologist (pediatric or adult, depending on the case) on hospital letterhead, stamped, addressing the SMA diagnosis with confirmatory genetic testing (homozygous SMN1 deletion or compound heterozygous SMN1 mutation, with SMN2 copy number where available), the SMA type (Type 1, 2, 3, or 4), prior treatment history (untreated; previously on Evrysdi; previously on Zolgensma), and the specific clinical case for intrathecal nusinersen.

The dosing plan referenced in the letter is the FDA-labeled schedule: four loading doses of 12 mg (one full 5 mL vial) at Day 0, Day 14, Day 28, and Day 63, followed by 12 mg maintenance dosing every four months indefinitely. A typical first-year patient receives 6 doses; subsequent years require 3 doses per year. The clinical letter is accompanied by the recent prescription specifying brand name, INN (nusinersen), strength (12 mg per 5 mL vial), and quantity, patient identifier documentation (national ID or passport), physician licensing verification through the Egyptian Medical Syndicate and the Ministry of Health, manufacturer details from Biogen including FDA approval reference, the destination dispensing facility license (the treating hospital pharmacy or licensed specialty importer pharmacy), the chain-of-custody plan for refrigerated shipment (2 to 8 degrees Celsius), and the procedural plan for intrathecal administration including any interventional radiology guidance requirements.

The monitoring plan referenced in the letter aligns with the FDA label: platelet count, coagulation laboratory testing (PT, PTT, INR), and quantitative spot urine protein testing at baseline and prior to each dose, with renal function (serum creatinine and cystatin C) monitored periodically. The treating center performs these labs on the day of or in the days before each scheduled dose. Routine EDA personal-import authorizations for well-documented rare-disease cases typically process in a 3 to 6 week window once a complete package is submitted. Complex cases can extend to 8 to 14 weeks. EDA reserves discretion at every step. Reserve Meds does not promise EDA timelines and is not the filer.

Where Spinraza gets dispensed in Egypt

The Egyptian institutional map for Spinraza is anchored at the major academic and specialty hospitals with pediatric neurology, adult neurology, and intrathecal procedural capability. Cairo University Hospitals (Kasr Al Ainy) maintains the largest academic neurology program in Egypt and the Middle East, with a Drug Information Center, dedicated pediatric units, and routine experience with imported specialty drugs. Ain Shams University Hospitals operates a parallel academic neurology program with strong pediatric services.

Children's Cancer Hospital Egypt 57357, while primarily an oncology institution, has the Personalized Medication Management Unit (the first pharmacogenetics unit of its kind in Egypt and the Arab world) and routine experience importing pediatric specialty drugs; CCHE 57357 supports coordination for pediatric SMA cases where the institutional fit is appropriate. Dar Al Fouad Hospital (JCI-accredited since 2005, with a Cleveland Clinic cooperation history) operates active neurology and neuroscience services and has import pharmacy infrastructure. As-Salam

International Hospital and the Cleopatra Hospitals Group support specialty neurology cases through their import pharmacy and outpatient infusion suites.

For patients in smaller cities or governorates outside Cairo, Giza, and Alexandria, the practical path is referral or co-management with one of these centers, with the EDA filing routed through the major institution's import pharmacy or through a licensed Cairo-based specialty importer.

Real cost picture for Spinraza in Egypt

US wholesale acquisition cost (WAC) for Spinraza is approximately USD 125,000 per 12 mg vial (Biogen-stated WAC at launch, maintained as the reference WAC). At the May 2026 USD to EGP rate near 52 to 53, a single vial converts to roughly EGP 6.5 million at WAC. First-year cost (6 doses) at US WAC is approximately USD 750,000; subsequent years (3 doses per year) at US WAC are approximately USD 375,000. International cash-pay private-import pricing in third countries typically reflects ex-US wholesaler pricing plus the Reserve Meds coordination fee, customs, freight, and treatment-center procedural costs. Per-dose all-in delivered cost to an Egyptian named-patient case is materially below US WAC in most documented patterns.

International cold-chain logistics from the US source to Cairo International Airport, the dominant Egyptian import gateway, typically run USD 400 to 1,500 per shipment depending on volume, temperature class (2 to 8 degrees Celsius for Spinraza), and route. Regulatory documentation handling fees on the Egyptian side vary by dispensing facility and importer. Reserve Meds itemizes the concierge fee on the firm quote and does not bundle it.

Reserve Meds quotes in USD and accepts USD wire transfers. The EGP has lost more than 70 percent of its value against the US dollar since early 2022; quoting in USD insulates the patient from intra-case currency drift. Local insurer behavior for Spinraza named-patient cases varies. Bupa Egypt, AXA Egypt, MetLife Egypt, Allianz Egypt, and Misr Insurance assess case-by-case. UHIA does not currently cover most specialty imports. Cash-pay is the default operating posture, and many families later recover a portion through private insurance where coverage applies.

Typical timeline for Spinraza in Egypt

For routine, well-documented SMA cases at a major institution, the EDA layer for the first authorization typically resolves in 3 to 6 weeks once the complete file is submitted. Complex first-time cases or cases with unusual documentation gaps can extend to 8 to 14 weeks. Cold-chain logistics from the US source to the Cairo treatment center add several days to a week to the active shipment window, with the 14-day room-temperature stability tolerance in the FDA label providing operational margin for customs delays. The clinical timeline is then set by the FDA-labeled loading schedule: Day 0, Day 14, Day 28, and Day 63 for the four loading doses, followed by maintenance every four months. For pediatric SMA Type 1, time-to-first-dose pressure is acute and Reserve Meds operates with rapid intake and pre-staged cold-chain. For SMA Type 2, 3, and 4, the cadence is steadier and operational continuity over years is the priority.

What your physician needs to provide

The clinical justification letter is the cornerstone of any Spinraza case file in Egypt. The letter, signed by a treating neurologist holding active Egyptian Medical Syndicate registration and a Ministry of Health license, addresses the patient's SMA diagnosis with confirmatory genetic testing (homozygous SMN1 deletion or compound heterozygous SMN1 mutation, with SMN2 copy number where available, ICD-10 G12.x), the SMA type, severity, prior treatment history, and

the specific clinical case for intrathecal nusinersen. The dosing plan references the FDA label four-loading-dose schedule followed by maintenance every four months, with platelet, coagulation, and renal monitoring per the label at baseline and prior to each dose.

The intrathecal administration plan is referenced in the letter, including procedural capability (lumbar puncture by a trained neurologist), and for patients with scoliosis, prior spinal fusion, or other anatomic challenges (common in older SMA Type 2 and Type 3 patients), any interventional radiology guidance requirements. The dispensing facility license is included; the receiving hospital pharmacy must hold a valid Egyptian pharmacy or hospital license. Reserve Meds supplies the US-side documentation kit (manufacturer-direct sourcing confirmation, cold-chain validation, customs documentation) so the treating physician and the institutional pharmacy team have the regulatory layer prepared in parallel.

Common questions about Spinraza in Egypt

Will Bupa Egypt, AXA, MetLife, or Allianz cover Spinraza? Each plan assesses named-patient imports case-by-case. Some plans reimburse a percentage when the drug treats a covered indication even if the specific product is not on a local formulary; many require pre-authorization. Reserve Meds supplies the documentation an insurer needs to assess. The claim filing remains with the patient or the hospital. Cash-pay is the default posture, with many families later recovering a portion where coverage applies. UHIA does not currently cover most specialty imports.

What is the safety profile? The most common adverse reactions in clinical trials were lower respiratory infection and constipation. Two warnings carry operational weight: thrombocytopenia and coagulation abnormalities (including acute severe thrombocytopenia have been reported), and renal toxicity including potentially fatal glomerulonephritis. The intrathecal procedure itself carries the usual lumbar puncture risks (post-LP headache, back pain, infection). Per the FDA label, platelet count, coagulation laboratory testing, and quantitative spot urine protein testing are required at baseline and prior to each dose.

Why Spinraza versus Evrysdi or Zolgensma? Spinraza has the longest real-world evidence base in SMA and works across all ages and types, including adult patients. Evrysdi is an oral daily small molecule preferred where oral administration is critical or where intrathecal access is anatomically difficult. Zolgensma is a one-time IV gene therapy restricted by age (under two years) and weight. The clinical decision rests with the treating neurologist; Reserve Meds does not advise on therapeutic selection.

Can adults with SMA Type 3 receive Spinraza in Egypt? The FDA label is age-agnostic. Real-world evidence in adults with SMA Type 3 has shown functional stabilization in many patients, though magnitude of benefit varies. For adults with scoliosis or spinal fusion, interventional radiology guidance may be required for intrathecal access, which constrains site selection to centers with that capability.

What is the typical course duration? Indefinite. Spinraza is a chronic, lifelong therapy with maintenance dosing every four months. There is no defined stopping point under the approved label.

Can the drug ship directly to my home? No. The dispensing facility must hold a valid Egyptian pharmacy or hospital license. For Spinraza, the medicine ships to the treatment center where the lumbar puncture is performed. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.

Where Reserve Meds fits in Spinraza cases

Reserve Meds is a US-based concierge coordinator. For a Spinraza inquiry from an Egyptian family, the working unit is treating-center identification, documentation kit preparation, US-side sourcing, international cold-chain logistics to Cairo International Airport, and continuous coordination through the loading-dose phase and the multi-year maintenance cadence. The clinical decisions remain with the treating neurologist. The regulatory authority remains EDA. The intrathecal administration remains with the licensed Egyptian dispensing facility.

What Reserve Meds carries: identification of the treating center with intrathecal procedural capability and willingness to dose imported product, preparation of the documentation kit with Arabic-language patient summaries where requested, manufacturer-direct sourcing confirmation, validated 2 to 8 degrees Celsius cold-chain shippers, customs and chain-of-custody documentation, EPVC pharmacovigilance reference embedded in the physician kit, and a single named coordinator who runs the case in both English and Arabic through the loading-dose phase and the every-four-months maintenance cadence over the life of therapy. Reserved for you.

Next step

If your family is considering Spinraza for spinal muscular atrophy in Egypt, the first step is a coordinated intake that confirms eligibility, treating-center fit, and a transparent firm quote. The waitlist request prefills the relevant context so the coordinator who reaches out is already oriented to your case.

Reserved for you.

About Spinraza

Spinal muscular atrophy (all types, all ages)
Manufacturer: Biogen
Modality: Intrathecal antisense oligonucleotide
Full drug page →

About Egypt

North Africa, MENA
Authority: EDA
Pathway: Personal Importation
Full country page →

Related

Zolgensma in Egypt
Evrysdi (risdiplam)
Spinal muscular atrophy
Named-patient pathways

Review & oversight. Content on this page is reviewed by Reserve Meds's clinical and regulatory team. A US-licensed pharmacist reviews every prescription before dispensing. Regulatory posture is informational, not legal advice; case-specific questions route to

retained outside counsel. Review methodology ›

Last medically reviewed: 2026-05-12.